Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind placebo-controlled trial of ibodutant in female IBS-D
2013-000895-14Phase 3Terminated
- Sponsor
- Menarini Group
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing ibodutant 10 mg once daily with placebo (2 arms). Primary endpoint: Primary Efficacy Endpoint. Started Nov 2013; status: terminated.
02
Drugs
ibodutant
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on 2013-000895-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000895-14.